Market Overview:
The global gabapentin enacarbil market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of chronic diseases, such as post-herpetic neuralgia (PHN) and restless legs syndrome (RLS), and rising geriatric population. In addition, growing awareness about the benefits of gabapentin enacarbil is also contributing to the growth of this market. However, patent expiry of key products in this market is likely to restrain the growth of this market during the forecast period. Based on type, the global gabapentin enacarbil market has been segmented into capsule and tablet. The capsule segment accounted for a larger share than that of tablet in 2017 and is expected to maintain its dominance throughout the forecast period.
Product Definition:
Gabapentin enacarbil (GEn) is a prodrug of gabapentin, used as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. It is marketed under the brand name Horizant.
Capsule:
Capsule is a small container that holds the medicine and it's used to administer the drug by mouth. It can be oral tablets, capsules or even injections. The size of capsule depends on what kind of medicine it contains, for instance, a liquid needs smaller container than a solid dose does.
Tablet:
Tablet is a form of drug delivery technology that has gained popularity in the pharmaceutical industry. It is a solid dosage form for drugs, which are mostly administered to patients by mouth. The most commonly used tablets are gabapentin and phenobarbital. Other types of tablets include film-coated, effervescent, and sublingual tablets as well as sustained-release (SR) tablets.
Application Insights:
The others segment dominated the global gabapentin enacarbil market in terms of revenue share in 2017. This is due to the presence of other applications for this drug, such as post-operative pain management and neuropathic pain. Gabapentin also finds application in various conditions related to sleepiness including restless legs syndrome (RLS) and periodic limb movement disorder (PLMD). Owing to its effectiveness, low risk of side effects, and affordable prices, it has become one of the most preferred drugs for treating these disorders. Thus, increasing usage for PLMD treatment coupled with growing preference towards sleeping pills is expected to drive demand over the forecast period.
Gabapentin also finds application as an anticonvulsant agent owing to its ability to block voltage-sensitive sodium channels; this property has led researchers toward studying its potential use as a therapeutic tool against epilepsy since 1996 when it was first introduced by Pfizer under the brand name Neurontin®.
Regional Analysis:
North America dominated the global market in terms of revenue in 2017. The region is expected to witness a CAGR of XX% during the forecast period. This can be attributed to factors such as high Gabapentin dose and usage, availability of highly advanced healthcare infrastructure, and rising awareness about neuropathic pain management treatment options among patients. Moreover, increasing government initiatives for quality improvement are also expected to drive regional growth over the forecast period. For instance, GABAPENTIN PATCH (gabapentin/fentanyl patch) was approved by FDA in December 2015 for post-herpetic neuralgia treatment under brand name FENTANYL PACHEMARIL ( Pfizer).
Asia Pacific is anticipated to register significant growth during the forecast years due to growing geriatric population base coupled with rising incidence rates of PHN & RLS among individuals aged 50 years.
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace and this is expected to drive the demand for Gabapentin Enacarbil in the coming years.
- Rising prevalence of neuropathic pain: The prevalence of neuropathic pain is increasing due to various factors such as aging, diabetes, and obesity. This is expected to boost the demand for Gabapentin Enacarbil in the near future.
- Growing awareness about Gabapentin Enacarbil: There is a growing awareness about the benefits of Gabapentin Enacarbil among healthcare professionals and patients alike, which is likely to propel its market growth in the coming years.
- Availability of generic versions: The availability of generic versions of Gabapentin Enacarbil at affordable prices has made it more accessible to patients, thereby driving its market growth globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gabapentin Enacarbil Market Research Report
By Type
Capsule, Tablet
By Application
Post-Herpetic Neuralgia (PHN), Restless Legs Syndrome (RLS), Others
By Companies
Arbor Pharma, Astellas, GlaxoSmithKline, Glenmark Pharma, Pfizer, Depomed, Teva, Mylan, Novartis, Apotex, Sun Pharmaceutical, Aurobindo Pharma, Intas, Amneal, Marksans Pharma, Alkem, Jiangsu Enhua, Jiangsu Hengrui, Sailike Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
166
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Gabapentin Enacarbil Market Report Segments:
The global Gabapentin Enacarbil market is segmented on the basis of:
Types
Capsule, Tablet
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Post-Herpetic Neuralgia (PHN), Restless Legs Syndrome (RLS), Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Arbor Pharma
- Astellas
- GlaxoSmithKline
- Glenmark Pharma
- Pfizer
- Depomed
- Teva
- Mylan
- Novartis
- Apotex
- Sun Pharmaceutical
- Aurobindo Pharma
- Intas
- Amneal
- Marksans Pharma
- Alkem
- Jiangsu Enhua
- Jiangsu Hengrui
- Sailike Pharma
Highlights of The Gabapentin Enacarbil Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsule
- Tablet
- By Application:
- Post-Herpetic Neuralgia (PHN)
- Restless Legs Syndrome (RLS)
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gabapentin Enacarbil Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gabapentin is a medication used to treat seizures. Gabapentin enacarbil is a form of gabapentin that is taken by mouth. It works by reducing the number of seizures someone has.
Some of the key players operating in the gabapentin enacarbil market are Arbor Pharma, Astellas, GlaxoSmithKline, Glenmark Pharma, Pfizer, Depomed, Teva, Mylan, Novartis, Apotex, Sun Pharmaceutical, Aurobindo Pharma, Intas, Amneal, Marksans Pharma, Alkem, Jiangsu Enhua, Jiangsu Hengrui, Sailike Pharma.
The gabapentin enacarbil market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gabapentin Enacarbil Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gabapentin Enacarbil Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gabapentin Enacarbil Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gabapentin Enacarbil Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gabapentin Enacarbil Market Size & Forecast, 2018-2028
4.5.1 Gabapentin Enacarbil Market Size and Y-o-Y Growth
4.5.2 Gabapentin Enacarbil Market Absolute $ Opportunity
Chapter 5 Global Gabapentin Enacarbil Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gabapentin Enacarbil Market Size Forecast by Type
5.2.1 Capsule
5.2.2 Tablet
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gabapentin Enacarbil Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gabapentin Enacarbil Market Size Forecast by Applications
6.2.1 Post-Herpetic Neuralgia (PHN)
6.2.2 Restless Legs Syndrome (RLS)
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gabapentin Enacarbil Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gabapentin Enacarbil Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gabapentin Enacarbil Analysis and Forecast
9.1 Introduction
9.2 North America Gabapentin Enacarbil Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gabapentin Enacarbil Market Size Forecast by Type
9.6.1 Capsule
9.6.2 Tablet
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gabapentin Enacarbil Market Size Forecast by Applications
9.10.1 Post-Herpetic Neuralgia (PHN)
9.10.2 Restless Legs Syndrome (RLS)
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gabapentin Enacarbil Analysis and Forecast
10.1 Introduction
10.2 Europe Gabapentin Enacarbil Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gabapentin Enacarbil Market Size Forecast by Type
10.6.1 Capsule
10.6.2 Tablet
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gabapentin Enacarbil Market Size Forecast by Applications
10.10.1 Post-Herpetic Neuralgia (PHN)
10.10.2 Restless Legs Syndrome (RLS)
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gabapentin Enacarbil Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gabapentin Enacarbil Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gabapentin Enacarbil Market Size Forecast by Type
11.6.1 Capsule
11.6.2 Tablet
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gabapentin Enacarbil Market Size Forecast by Applications
11.10.1 Post-Herpetic Neuralgia (PHN)
11.10.2 Restless Legs Syndrome (RLS)
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gabapentin Enacarbil Analysis and Forecast
12.1 Introduction
12.2 Latin America Gabapentin Enacarbil Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gabapentin Enacarbil Market Size Forecast by Type
12.6.1 Capsule
12.6.2 Tablet
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gabapentin Enacarbil Market Size Forecast by Applications
12.10.1 Post-Herpetic Neuralgia (PHN)
12.10.2 Restless Legs Syndrome (RLS)
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gabapentin Enacarbil Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gabapentin Enacarbil Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gabapentin Enacarbil Market Size Forecast by Type
13.6.1 Capsule
13.6.2 Tablet
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gabapentin Enacarbil Market Size Forecast by Applications
13.10.1 Post-Herpetic Neuralgia (PHN)
13.10.2 Restless Legs Syndrome (RLS)
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gabapentin Enacarbil Market: Competitive Dashboard
14.2 Global Gabapentin Enacarbil Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Arbor Pharma
14.3.2 Astellas
14.3.3 GlaxoSmithKline
14.3.4 Glenmark Pharma
14.3.5 Pfizer
14.3.6 Depomed
14.3.7 Teva
14.3.8 Mylan
14.3.9 Novartis
14.3.10 Apotex
14.3.11 Sun Pharmaceutical
14.3.12 Aurobindo Pharma
14.3.13 Intas
14.3.14 Amneal
14.3.15 Marksans Pharma
14.3.16 Alkem
14.3.17 Jiangsu Enhua
14.3.18 Jiangsu Hengrui
14.3.19 Sailike Pharma
